Advisor Partners II’s AstraZeneca AZN Stock Holding History

Advisor Partners II’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$4.27M	Buy	31,495 +6,363	+25%	+$869K	0.17%	117
2023 Q2	$3.6M	Buy	25,132 +813	+3%	+$120K	0.17%	116
2023 Q1	$3.38M	Buy	24,319 +1,934	+9%	+$260K	0.19%	107
2022 Q4	$3.04M	Buy	22,385 +4,747	+27%	+$595K	0.19%	110
2022 Q3	$1.94M	Buy	+17,638	New	+$2.24M	0.15%	147

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Advisor Partners II's AZN Position: Q3 2023 in Review

Advisor Partners II increased its AstraZeneca (AZN) stake by 25% in Q3 2023, buying an estimated $869K and bringing the position to 31,495 shares worth $4.27M. The position accounts for 0.17% of the portfolio, ranked #117.

Advisor Partners II first reported a position in AZN in Q3 2022 and has held it in 5 quarters since. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Advisor Partners II held 31,495 shares of AstraZeneca worth $4.27M as of Q3 2023.
Advisor Partners II bought 6,363 AstraZeneca shares in Q3 2023, an estimated $869K.
AstraZeneca made up 0.17% of Advisor Partners II's portfolio in Q3 2023, its #117 holding.
Advisor Partners II first reported a position in AstraZeneca in Q3 2022 and has held it in 5 quarters since.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.